Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

50.05 +0.19 (+0.37%)
Streaming Delayed Price Updated: 11:37 AM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
89 90 Next >
Eli Lilly’s Weight Loss Pill Succeeds In Phase 3 Trials On Type-2 Diabetes Patients
The company says orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase 3 trial. 
Via Stocktwits
Topics Economy Government Stocks
Eli Lilly Stock Rockets On Weight-Loss Pill Progress
Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles. 
Via Investor's Business Daily
Topics Government
While growth is established for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), the stock's valuation remains reasonable.
Discover NOVO-NORDISK A/S-SPONS ADR, an undervalued growth gem. NYSE:NVO is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
This Microsoft Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
Viking Therapeutics Stock Pops But Struggles to Hold Gains
VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington 
Via MarketBeat
Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts
FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility. 
Via Benzinga
Topics Economy
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential. 
Via Benzinga
Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch
Mounjaro's launch in India sparks a surge in patient demand as Eli Lilly gains a market edge ahead of Novo Nordisk and upcoming generic competition. 
Via Benzinga
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517. 
Via Stocktwits
Topics Economy
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
Recent Filing Shows That Rep. Scott Franklin Bought Over $16K Worth of Novo Nordisk Stock
 
Via Benzinga
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
Is Novo Nordisk Gaining or Losing Market Support?
 
Via Benzinga
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care. 
Via Investor's Business Daily
Topics Government
Hims’ Weight Loss Expansion: Real Growth or Just Hype?
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite? 
Via MarketBeat
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Government
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound
CMS finalizes 2026 Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries. 
Via Benzinga
Topics Government
Retail Traders Prefer Novo Nordisk To Eli Lilly After Medicare Shuts Door On Obesity Drug Coverage — But There's More
However, Morgan Stanley sees limited impact on Lilly from the CMS decision as the proposed coverage appeared to apply only to a subset of the Medicare obesity population 
Via Stocktwits
Topics Government World Trade
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic drug market may be negatively affected. 
Via Benzinga
Topics World Trade
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): good value for what you're paying.
NOVO-NORDISK A/S-SPONS ADR may be an undervalued stock option. NYSE:NVO retains a strong financial foundation and an attractive price tag. 
Via Chartmill
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. 
Via Investor's Business Daily
Topics Government
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Via The Motley Fool
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it. 
Via Investor's Business Daily
Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales
Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results. 
Via Benzinga
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Via The Motley Fool
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform. 
Via Benzinga
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform. 
Via Investor's Business Daily
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.